Based in the Wuhan Economic and Technological Development Zone, Wuhan Hiteck Biological Pharma Co is a high-tech biopharmaceutical company focusing on the research, development and production of drugs in the nervous system and with a focus on oncology.
The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in August 2017.
The main business is the production and sale of biological engineering products, freeze-dried powder injections and the import and export of products and technologies.
Currently, the company has production approvals in China from the authorities for 24 biological products and chemicals.
The company's grounds cover a total area of 138,000 square meters, its buildings cover more than 61,000 sq m and it has over 14,800 sq m of production plants that meet national GMP standards.
At present, the company has developed and sold a new national first-class biomedical drug -- a nerve growth factor called NGF (Jin Lujie), administered by injection.
A new national first-class genetically engineered biological drug -- the recombinant allosteric human tumor necrosis factor-related apoptosis inducing ligand project (Circular Permuted TRAIL , CPT for short) -- is in Phase III clinical stage.
Address: Hiteck Science and Technology Park, Wuhan Economic and Technological Development Zone, Wuhan, Hubei province
